ADRESA
Put doktora Goldmana 4
Sremska Kamenica
Srbija
PIŠITE NAM
senologija@gmail.com
SAŽETAK
Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer:
A Delphi Consensus
Lazar Popovi´c 1,* , Simona Borštnar 2
, Ivana Božovi´c-Spasojevi´c 3
, Ana Cvetanovi´c 4
, Natalija Dedi´c Plaveti´c 5
,
Radka Kaneva 6
, Assia Konsoulova 7,8, Erika Matos 2
, Snježana Tomi´c 9 and Eduard Vrdoljak 9
1 Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
2
Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia; sborstnar@onko-i.si (S.B.); ematos@onko-i.si (E.M.)
3
Institute for Oncology and Radiology of Serbia, Medical Faculty, University of Belgrade,
11000 Belgrade, Serbia; ivanabs@ncrc.ac.rs
4 University Clinical Centre Niš, Medical Faculty of Niš, 18000 Niš, Serbia; ana.cvetanovic@medfak.ni.ac.rs
5 University Clinical Hospital Center Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
6 Molecular Medicine Center, Medical University of Sofia, 1431 Sofia, Bulgaria; kaneva@mmcbg.org
7 University Cancer Hospital Prof. Ivan Chernozemski, 1756 Sofia, Bulgaria; akonsoulova@sbaloncology.bg
8 Department of Preclinical and Clinical Disciplines, Faculty of Social Health and Healthcare, University Prof.
A. Zlatarov, 8000 Burgas, Bulgaria
9 Clinical Hospital Center Split, University of Split School of Medicine, 21000 Split, Croatia;
stomic@mefst.hr (S.T.); eduard.vrdoljak@mefst.hr (E.V.)
* Correspondence: lazar.popovic@mf.uns.ac.rs
Simple Summary: Metastatic breast cancer (mBC) carries a huge burden for patients and
healthcare systems globally. Optimal treatment is of paramount importance to streamline
the treatment journey. In HR+/HER2− mBC, at disease progression on first-line therapy,
the choice of next treatment lines should be guided not only by the presence of specific
targetable mutations, but also by evidence of efficacy and safety from clinical trials and
access to genetic testing and medications. The aim of the Delphi process is to gain consensus
(at least 70% agreement) on the perspective of treatment strategies from experts in the field.
The outcome of Delphi discussions is an algorithm for the second line in HR+/HER2−
mBC. Clinicians may find it useful in their current practice and use it as a basis for the
treatment individualization strategy, which must remain the core principle of our actions.